Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Paola Stefanoni, Jacopo Micozzi, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Gabriele Buda, Sr., Flavia Lotti, Carmine Liberatore, Antonio Lazzaro, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Lorenzo De Paoli, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Pietro Benvenuti, Claudio Cerchione, Cirino Botta, Elisabetta Antonioli, Nicola Sgherza, Sara Aquino, Giuseppe Mele, Gregorio Barila, Salvatore Palmieri, Ombretta Annibali, Rosario Bianco, Massimiliano Arangio Febbo, Gloria Margiotta Casaluci, Angela Rago, Raffaele Fontana, Francesca Farina, Ernesto Vigna, Antonella Bruzzese, Catello Califano, Angela Amendola, Daniela Roccotelli, Alessandra Lombardo, Annalisa Citro, Giuseppina Uccello, Renato Zambello, Alessandro Maggi, Santo Neri, Michele Monachesi, Alessandro Gozzetti, Vittorio Montefusco, Marino Brunori, Nicola Di Renzo, Marta Coscia, Valerio De Stefano, Antonino Neri, Francesco Di Raimondo, Fortunato Morabito, Pellegrino Musto, Massimo Gentile

Blood (2024) 144 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2024-206008

Published: 2024

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Blood (2024) 144 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2024-201630

Published: 2024

Journal Articles

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Blood (2024) 144 (Supplement 1): 5153.

https://doi.org/10.1182/blood-2024-204021

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Blood (2023) 142 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2023-191911

Published: 2023

Journal Articles

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Blood (2023) 142 (Supplement 1): 208.

https://doi.org/10.1182/blood-2023-177564

Published: 2023

Journal Articles

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Blood (2023) 142 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2023-179922

Published: 2023

Journal Articles

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 4.

https://doi.org/10.1182/blood-2023-177546

Published: 2023

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)

Blood (2023) 142 (Supplement 1): 205.

https://doi.org/10.1182/blood-2023-177673

Published: 2023

Journal Articles

The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 115.

https://doi.org/10.1182/blood-2021-145977

Published: 2021

Journal Articles

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma

Blood (2021) 137 (22): 3027–3036.

https://doi.org/10.1182/blood.2020009507

Published: 2021

Includes: Supplemental data

Journal Articles

Minimal Residual Disease (MRD) at 10 -6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication )

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141538

Published: 2020

Journal Articles

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, MD, Diana Giannarelli, PhD, Loredana Pettine, MD, Laura Paris, MD, Lucia Tognazzi, Magda Marcatti, MD, Elisabetta Antonioli, MD, Francesca Fioritoni, MD, Angela Bonalumi, MD, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, MD, Daniele Derudas, MD, Agostina Siniscalchi, Sara Pezzatti, MD, Renato Zambello, Annalisa Citro, MD, Angelo Belotti, Alessandra Lombardo, MD, Federico Vozella, MD, Adelina Sementa, MD, Ugo Consoli, MD, Alfredo Molteni, MD, Niccolò Frungillo, MD, Massimo Gentile, MD, Gabriele Buda, MD PhD, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, MD, Alessandro Inzoli, MD, Valeria Ferla, MD, Francesca Gaia Rossi, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Federica Elia, MD, Vittorio Del Fabro, MD, Guido Montanaro, MD, Francesca Cavallaro, MD, Monica Galli, Luca Baldini, MD PhD

Blood (2019) 134 (Supplement_1): 5555.

https://doi.org/10.1182/blood-2019-125098

Published: 2019

Journal Articles

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Blood (2018) 132 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2018-99-115340

Published: 2018

Journal Articles

Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study in 596 Patients of the Registro Italiano Trombocitemie (RIT)

Blood (2015) 126 (23): 4071.

https://doi.org/10.1182/blood.V126.23.4071.4071

Published: 2015

Journal Articles

Initial Therapeutic Approach and Relationship with Clinical and Biological Characteristics at Diagnosis in 2418 Patients of the Registro Italiano Trombocitemie (RIT)

Blood (2014) 124 (21): 3196.

https://doi.org/10.1182/blood.V124.21.3196.3196

Published: 2014

Journal Articles

Thrombosis History and Relationship With Low Thrombocytosis, Leukocytosis, and Other Characteristics At Diagnosis In 977 Essential Thrombocythemia Patients A Multivariate Analysis Of The Registro Italiano Trombocitemie (RIT)

Luigi Gugliotta, MD, Alessandra Iurlo, MD, Alessia Tieghi, MD, Gabriele Gugliotta, MD, Anna Candoni, MD, Elisa Rumi, MD, Elisabetta Antonioli, MD, Alessandra Ricco, Monica Lunghi, MD, Rosario Potito Scalzulli, MD, Anna Rita Scortechini, MD, Katia Codeluppi, Bruno Martino, MD, Alfredo Dragani, MD, Andrea Patriarca, MD, Vincenzo Martinelli, MD, Giorgia Battipaglia, MD, Maria Luigia Randi, MD, Elisabetta Cosi, MD, Anna Marina Liberati, MD, Viviana Appolloni, MD, Nilla Maschio, MD, Lucia Mastrullo, MD, Maria Rosaria Villa, MD, Maria Rosaria Esposito, MD, Nicola Cantore, MD, Fausto Palmieri, MD, Maria Langella, MD, Flavia Rivellini, MD, Maria Gabriella Mazzucconi, MD, Cristina Santoro, MD, Ercole De Biasi, MD, Angela Rago, MD, Nicola Polverelli, MD, Pierangelo Spedini, MD, Emma Cacciola, MD, Rossella R Cacciola, MD, Ivana Pierri, MD, Laura Mitsheunig, MD, Marzia Salvucci, Ferdinando Porretto, MD, Andrea Piccin, MD, Umberto Santoro, Gianluca Gaidano, Giuseppe Cimino, MD, Francesco Lanza, MD, Agostino Cortelezzi, MD, Giuseppe Tagariello, MD, Serena Rupoli, MD, Giorgina Specchia, Francesco Passamonti, MD, Alessandro M. Vannucchi, MD, Fabrizio Pane, Nicola Vianelli, MD, Rossella Miglio, Paola Monari

Blood (2013) 122 (21): 2829.

https://doi.org/10.1182/blood.V122.21.2829.2829

Published: 2013

Journal Articles

Role of the Somatic Mutation Rate in Patients with Classical Myeloproliferative Neoplasms (MPN) with and without Other Neoplasms

Margherita Berardi, BS, Tommaso Rondelli, BS, Maria Chiara Susini, MD, Annamaria Pellecchia, BS, Elisabetta Antonioli, MD, Luca Boni, MD, Lucio Luzzatto, MD, FRCP, FRCPath, Alessandro M. Vannucchi, MD, Rosario Notaro, MD

Blood (2012) 120 (21): 5055.

https://doi.org/10.1182/blood.V120.21.5055.5055

Published: 2012

Journal Articles

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

Blood (2012) 120 (6): 1197–1201.

https://doi.org/10.1182/blood-2012-01-403279

Published: 2012

Includes: Supplemental data

Journal Articles

Risk of second cancers in chronic myeloproliferative neoplasms

Maria Chiara Susini, Giovanna Masala, Elisabetta Antonioli, Lisa Pieri, Paola Guglielmelli, Domenico Palli, Alberto Bosi, Alessandro M. Vannucchi

Blood (2012) 119 (16): 3861–3862.

https://doi.org/10.1182/blood-2011-12-401455

Published: 2012

Journal Articles

A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Blood (2011) 118 (21): 1746.

https://doi.org/10.1182/blood.V118.21.1746.1746

Published: 2011

NARROW

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)

The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma

Minimal Residual Disease (MRD) at 10 -6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication )

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study in 596 Patients of the Registro Italiano Trombocitemie (RIT)

Initial Therapeutic Approach and Relationship with Clinical and Biological Characteristics at Diagnosis in 2418 Patients of the Registro Italiano Trombocitemie (RIT)

Thrombosis History and Relationship With Low Thrombocytosis, Leukocytosis, and Other Characteristics At Diagnosis In 977 Essential Thrombocythemia Patients A Multivariate Analysis Of The Registro Italiano Trombocitemie (RIT)

Role of the Somatic Mutation Rate in Patients with Classical Myeloproliferative Neoplasms (MPN) with and without Other Neoplasms

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

Risk of second cancers in chronic myeloproliferative neoplasms

A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only